Sponsor: Zeno Pharmaceuticals, Inc.
Protocol ZN-e4-001: A Phase I Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-e4 (KP-673) in Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor (EGFR) Mutations.
For more information please contact the clinical research department: 631-675-5075